The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Effects of Recombinant Apolipoprotein A-I Milano on Aortic Atherosclerosis in Apolipoprotein E–Deficient Mice
Abstract
Background —We previously reported marked inhibitory effects of recombinant apolipoprotein (apo) A-I Milano /phospholipid complex (A-I Milano /PC) on neointimal lesions in balloon-injured iliofemoral arteries of hypercholesterolemic rabbits. In this study, we tested the hypothesis that apo A-I Milano /PC would inhibit aortic atherosclerosis in apo E–deficient mice. Methods and Results —Thirty-five apo E–deficient mice fed a high-cholesterol diet were included in the study. Control mice were killed at 20 (n=8) or 25 (n=7) weeks. Treated mice received 18 injections of either 40 mg/kg apo A-I Milano /PC (n=15) or PC only (n=5) intravenously every other day from 20 weeks until death at 25 weeks. Aortic atherosclerosis was identified with Sudan IV staining. Lipid and macrophage contents of the aortic sinus plaques were measured after oil-red O and Mac-1 antibody staining, respectively, and quantified with computed morphometry. In control mice, from 20 to 25 weeks, aortic atherosclerosis increased by 59% (11±1% versus 17±5% of the aortic surface, P =.002), and lipid content increased by 45% (22±8% versus 32±6% of plaque area, P =.02) without a significant change in macrophage content (10.8±2% versus 13.2±6%). Compared with 20-week-old untreated control mice, PC only–treated mice at 25 weeks demonstrated a 32% increase in aortic atherosclerosis (11±1% versus 15±4%, P =.01) and an increase in lipid content (22±8% versus 47±3%, P <.0001) without a change in macrophage content (10.8±2% versus 11±2%). In comparison with 20-week-old untreated control mice, 25-week-old apo A-I Milano /PC–treated mice demonstrated no increase in aortic atherosclerosis (11±1% versus 10±4%, P =NS), a 40% reduction in lipid content (22±8% versus 13±8%, P =.01), and a 46% reduction in macrophage content (10.8±2% versus 5.8±2.9%; P =.03). Serum cholesterol levels were markedly elevated in all groups and did not change significantly with apo A-I Milano /PC or PC only. In vitro, apo A-I Milano /PC stimulated cholesterol efflux from cholesterol-loaded FU5AH hepatoma cell lines in a dose-dependent manner, whereas PC only or PC-free apo A-I Milano had no effect. Conclusions —Recombinant A-I Milano /PC prevented progression of aortic atherosclerosis and reduced lipid and macrophage content of plaques in apo E–deficient mice despite severe hypercholesterolemia. Thus, A-I Milano /PC may have a role in inhibiting progression and promoting stabilization of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Plump, A. S., Smith, J. D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J. G., Rubin, E. M., & Breslow, J. L. (1992) · Cell · doi:10.1016/0092-8674(92)90362-g · Cited by 2,263
Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Despre´s, J.-P. (1997) · Circulation · doi:10.1161/01.cir.95.1.69 · Cited by 1,077
Gardner, C. D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110029028 · Cited by 843
Cited by
Atherothrombosis and High-Risk Plaque
Fuster, V., Moreno, P. R., Fayad, Z. A., Corti, R., & Badimon, J. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.074 · Cited by 738
Kontush, A., & Chapman, M. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.1 · Cited by 647
Mechanisms of plaque vulnerability and rupture
Shah, P. K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02834-6 · Cited by 541
Self-citationDuivenvoorden, R., Tang, J., Cormode, D. P., Mieszawska, A. J., Izquierdo-Garcia, D., Ozcan, C., Otten, M. J., Zaidi, N., Lobatto, M. E., van Rijs, S. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms4065 · Cited by 442
Perspectives and opportunities for nanomedicine in the management of atherosclerosis
Lobatto, M. E., Fuster, V., Fayad, Z. A., & Mulder, W. J. M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3578 · Cited by 423
Metadata
- Authors
- Shah, P. K., Nilsson, J., Kaul, S., Fishbein, M. C., Ageland, H., Hamsten, A., Johansson, J., Karpe, F., & Cercek, B.
- Venue
- Circulation
- Published
- 1998-03-03
- Volume
- 97
- Issue
- 8
- Pages
- 780-785
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2072754618
- Cited by
- 239
- References
- 6
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.